AMGN241122C415000
- 0.05
- 0.000.00%
Amgen Newsroom
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Sticks to Their Buy Rating for Amgen (AMGN)
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
Amgen Initiated at Peer Perform by Wolfe Research
Wolfe Research Maintains Amgen(AMGN.US) With Hold Rating
Evercore Maintains Amgen(AMGN.US) With Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $383
Amgen Analyst Ratings
HSBC Adjusts Price Target on Amgen to $385 From $369
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $362 to $405
Amgen Analyst Ratings
Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $322 to $383
Amgen Is Maintained at Neutral by UBS
Amgen Analyst Ratings
Goldman Sachs Adjusts Price Target on Amgen to $375 From $369, Maintains Buy Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $322 to $405